AFP and eGFR are related to early and late recurrence of HCC following antiviral therapy.
Takao WatanabeYoshio TokumotoKouji JokoKojiro MichitakaNorio HoriikeYoshinori TanakaFujimasa TadaYoshiyasu KisakaSeiji NakanishiKazuhiko YamauchiHironori OchiAtsushi HiraokaSen YagiAtsushi YukimotoMasashi HirookaMasanori AbeYoichi HiasaPublished in: BMC cancer (2021)
Patients with higher post-treatment AFP in the early phase and those with lower post-treatment eGFR in the late phase had a high risk of HCC recurrence. The risk factors associated with HCC recurrence after DAA treatment were different between the early and late phases.